From Our Partners
Wednesday, June 29, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Inovio to Advance Ebola Vaccine to Human Trials

by Global Biodefense Staff
September 29, 2014

Inovio Pharmaceuticals Inc. last week announced plans to advance their DNA vaccine for the Ebola virus into human clinical trials in early 2015.

Results from the company’s preclinical testing of the vaccine showed 100% of vaccinated guinea pigs and mice were protected from death after being exposed to the Ebola virus.

Inovio is co-develop the vaccine with GeneOne Life Science Inc., a vaccine manufacturer based in Seoul, of which Inovio owns a minority stake.

Upon successful completion of Phase 1 studies, Inovio and GeneOne indicated they would jointly seek additional third-party funding and support to further develop and commercialize the vaccine.

“There are no proven agents to check the spread of Ebola, which is now becoming a health threat of global concern,” said Dr. J. Joseph Kim, Inovio president and chief executive. “We are therefore taking the steps…to establish the safety and immunogenicity of our Ebola vaccine in humans and be in a position to further advance these agents to help fight this challenging disease.”

Inovio’s Syncon DNA vaccine technology uses a DNA fragment with instructions that enable cells in the body to produce only the targeted antigen relating to a pathogen. Rather than being constrained by the paradigm of matching a preventive or therapeutic vaccine to a single pathogen strain, the SynCon vaccines are based on genetic code for a specific antigen from multiple strains of the target pathogen.

This adaptability potentially gives Inovio an advantage over other Ebola vaccine candidates. The SynCon antigens are designed to protect against multiple existing strains as well as changing strains of a virus.

Sources: AP, Inovio, Wall Street Journal

From Our Partners
Tags: EbolaVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC